Nanocarrier-based therapies for CNS tumors

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Current chemotherapeutic strategies for tumors of the CNS are largely ineffective. This is due, in part, to the lack of robust drug delivery systems. The blood-brain barrier hinders the passage of systemically delivered therapeutics, and the brain extracellular matrix limits the distribution and longevity of locally delivered agents. Drug-loaded nanocarriers represent a promising strategy to overcome these barriers. Due to their small size and versatile design, nanocarriers can be finely tuned to address specific drug delivery challenges. Here, we review the major advances in development of nanocarrier-based therapeutics for tumors of the CNS, with an emphasis on polymeric nanoparticles.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalCNS oncology
Volume3
Issue number2
DOIs
StatePublished - Mar 1 2014

Fingerprint

Drug Delivery Systems
Blood-Brain Barrier
Pharmaceutical Preparations
Nanoparticles
Extracellular Matrix
Neoplasms
Brain
Therapeutics

Keywords

  • blood–brain barrier
  • brain
  • convection-enhanced delivery
  • dendrimer
  • intracranial
  • liposome
  • micelle
  • nanocarrier
  • nanoparticle
  • polymer
  • systemic delivery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nanocarrier-based therapies for CNS tumors. / Patel, Toral R.

In: CNS oncology, Vol. 3, No. 2, 01.03.2014, p. 115-122.

Research output: Contribution to journalArticle

@article{052b0343bb644fe68e3b6c31e7c49b92,
title = "Nanocarrier-based therapies for CNS tumors",
abstract = "Current chemotherapeutic strategies for tumors of the CNS are largely ineffective. This is due, in part, to the lack of robust drug delivery systems. The blood-brain barrier hinders the passage of systemically delivered therapeutics, and the brain extracellular matrix limits the distribution and longevity of locally delivered agents. Drug-loaded nanocarriers represent a promising strategy to overcome these barriers. Due to their small size and versatile design, nanocarriers can be finely tuned to address specific drug delivery challenges. Here, we review the major advances in development of nanocarrier-based therapeutics for tumors of the CNS, with an emphasis on polymeric nanoparticles.",
keywords = "blood–brain barrier, brain, convection-enhanced delivery, dendrimer, intracranial, liposome, micelle, nanocarrier, nanoparticle, polymer, systemic delivery",
author = "Patel, {Toral R.}",
year = "2014",
month = "3",
day = "1",
doi = "10.2217/cns.14.2",
language = "English (US)",
volume = "3",
pages = "115--122",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Nanocarrier-based therapies for CNS tumors

AU - Patel, Toral R.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Current chemotherapeutic strategies for tumors of the CNS are largely ineffective. This is due, in part, to the lack of robust drug delivery systems. The blood-brain barrier hinders the passage of systemically delivered therapeutics, and the brain extracellular matrix limits the distribution and longevity of locally delivered agents. Drug-loaded nanocarriers represent a promising strategy to overcome these barriers. Due to their small size and versatile design, nanocarriers can be finely tuned to address specific drug delivery challenges. Here, we review the major advances in development of nanocarrier-based therapeutics for tumors of the CNS, with an emphasis on polymeric nanoparticles.

AB - Current chemotherapeutic strategies for tumors of the CNS are largely ineffective. This is due, in part, to the lack of robust drug delivery systems. The blood-brain barrier hinders the passage of systemically delivered therapeutics, and the brain extracellular matrix limits the distribution and longevity of locally delivered agents. Drug-loaded nanocarriers represent a promising strategy to overcome these barriers. Due to their small size and versatile design, nanocarriers can be finely tuned to address specific drug delivery challenges. Here, we review the major advances in development of nanocarrier-based therapeutics for tumors of the CNS, with an emphasis on polymeric nanoparticles.

KW - blood–brain barrier

KW - brain

KW - convection-enhanced delivery

KW - dendrimer

KW - intracranial

KW - liposome

KW - micelle

KW - nanocarrier

KW - nanoparticle

KW - polymer

KW - systemic delivery

UR - http://www.scopus.com/inward/record.url?scp=84925883197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925883197&partnerID=8YFLogxK

U2 - 10.2217/cns.14.2

DO - 10.2217/cns.14.2

M3 - Article

VL - 3

SP - 115

EP - 122

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 2

ER -